Arq. Bras. Cardiol. 2020; 114(4): 598-600
COVID-19 and the Heart
COVID-19 and the Heart
1,279
How to cite this article
Strabelli TMV, Uip DE. COVID-19 and the Heart. Arq. Bras. Cardiol. 2020;114(4):598-600.
Strabelli, Tânia Mara Varejão; Uip, David Everson. COVID-19 and the Heart. Arq. Bras. Cardiol., v. 114, n. 4, p. 598-600, Apr. 2020.
Strabelli, T. M. V., & Uip, D. E. (2020). COVID-19 and the Heart. Arq. Bras. Cardiol., 114(4), 598-600.
Strabelli, Tânia Mara Varejão and Uip, David Everson. COVID-19 and the Heart. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 4, [cited 2025-09-07], pp.598-600. Available from: <https://abccardiol.org/en/article/covid-19-and-the-heart/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.